Enhanced Production of EPA-Derived Anti-Inflammatory Metabolites after Oral Administration of a Novel Self-Emulsifying Highly Purified EPA Ethyl Ester Formulation (MND-2119)

• Published in: Journal of Atherosclerosis and Thrombosis Vol. 30; no. 12; pp. 1927 - 1949
• Main Authors: Wakabayashi, Hiroyuki, Arita, Makoto, Mori, Takuya, Ito, Hiroshi, Miyoshi, Toru, Naoe, Satoko, Yano, Takashi, Kanda, Shingo
• Format: Journal Article
• Language: English
• Published: Japan Japan Atherosclerosis Society 01.12.2023
• Subjects: Administration, Oral; Adult; Anti-Inflammatory Agents; Docosahexaenoic Acids; Eicosapentaenoic Acid; Esters; Fatty Acids; Humans; Inflammation; Male; Metablolite; MND-2119; Inflammation; MND-2119; Metablolite; Eicosapentaenoic acid
• ISSN: 1340-3478; 1880-3873; 1880-3873
• DOI: 10.5551/jat.64135

Aims: MND-2119 is a novel once-daily dose self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (EPA-E) and is approved as an antihyperlipidemia agent in Japan. It has improved absorption and achieves higher plasma EPA concentrations at Cmax than conventional EPA-E. In the JELIS trial, concomitant use of EPA-E with statin therapy significantly reduced atherosclerotic cardiovascular disease (ASCVD) risks. As a potential mechanism of action of EPA, endogenous formation of EPA-derived anti-inflammatory metabolites is receiving greater attention. This study aims to investigate the endogenous formation of EPA-derived anti-inflammatory metabolites following single and multiple administrations of MND-2119.Methods: Healthy adult male subjects were randomly assigned to a nonintervention (control) group, MND-2119 2-g/day group, MND-2119 4-g/day group, or EPA-E 1.8-g/day group for 7 days (N=8 per group). Plasma fatty acids and EPA-derived metabolites were evaluated. Peripheral blood neutrophils were isolated, and the production of EPA-derived metabolites from in vitro stimulated neutrophils was evaluated.Results: After single and multiple administrations of MND-2119 2 g/day, there were significant increases in plasma EPA concentration, 18-hydroxyeicosapentaenoic acid (18-HEPE), and 17,18-epoxyeicosatetraenoic acid compared with those of EPA-E 1.8 g/day. They were further increased with MND-2119 4 g/day administration. In neutrophils, the EPA concentration in the MND-2119 2-g/day group was significantly higher compared with that in the EPA-E 1.8-g/day group after multiple administration, and 18-HEPE production was positively correlated with EPA concentration. No safety issues were noted.Conclusions: These results demonstrate that MND-2119 increases the plasma and cellular concentrations of EPA and EPA-derived metabolites to a greater extent than conventional EPA-E formulations.